AIM ImmunoTech outlines Phase II study plans for long Covid fatigue
AIM ImmunoTech leadership offers new details on a potential Phase II trial of Ampligen in long Covid patients with chronic fatigue.
By
Follow @WillNewton19
William Newton is a Senior Reporter for Clinical Trials Arena and Pharmaceutical Technology, focusing on clinical trial design, rare diseases, and the central nervous system. Now based in New York City, he previously covered diabetes drug development at Close Concerns’ industry-facing publication in San Francisco. William holds a BA in Economics from Williams College.
AIM ImmunoTech leadership offers new details on a potential Phase II trial of Ampligen in long Covid patients with chronic fatigue.
By William NewtonThere are 100–400 million Dengue fever infections each year, and cases are quickly rising. How can manufacturers overcome obstacles…
By William NewtonIntrommune CEO Michael Nelson details plans for a Phase II trial in children with peanut allergies slated for late…
By William NewtonAfter Biogen all but waved the white flag on its once-promising Aduhelm, Clinical Trials Arena explores how Alzheimer’s disease…
By William NewtonSome ultra-rare diseases have fewer than 30 known patients globally. Is there an ethical and economical way to test…
By William NewtonCNM-Au8 clinical advisor Matthew Kiernan previews Clene’s planned Phase III ALS trial design, including biomarkers and target population.
By William NewtonNeuroSense CEO Alon Ben-Noon reveals the target patient population and outcome measures of a planned Phase IIb ALS trial…
By William NewtonThe 6-minute walk test has long been the consensus primary measure for Pompe disease drug studies, but some experts…
By William NewtonBrainStorm Cell Therapeutics is generating stem cells to test its ALS drug in a genetic subpopulation after missing the…
By William NewtonThank you for subscribing to Clinical Trials Arena